Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

ZANTE GREG

2. Date of Event Requiring Statement (MM/DD/YYYY) 1/4/2021

3. Issuer Name and Ticker or Trading Symbol

Viking Therapeutics, Inc. [VKTX]

(Last) (First) (Middle)

C/O VIKING THERAPEUTICS, INC., 12340 EL CAMINO REAL, SUITE 250

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___X___ Officer (give title below) _____ Other (specify below)
Chief Financial Officer /

(Street)

SAN DIEGO, CA 92130

(City) (State) (Zip)

5. If Amendment, Date Original Filed(MM/DD/YYYY)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value $0.00001 per share	21896 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)*
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	3/31/2021 ⁽²⁾	3/31/2030	Common Stock	17000	$4.68	D
Stock Option (Right to Buy)	1/3/2021 ⁽³⁾	1/3/2030	Common Stock	51000	$7.77	D
Stock Option (Right to Buy)	7/31/2020 ⁽⁴⁾	7/31/2029	Common Stock	42000	$7.69	D
Stock Option (Right to Buy)	1/15/2020 ⁽⁵⁾	1/15/2029	Common Stock	32000	$8.52	D
Stock Option (Right to Buy)	8/31/2018 ⁽⁶⁾	8/31/2028	Common Stock	7500	$13.07	D
Stock Option (Right to Buy)	⁽⁷⁾	4/30/2028	Common Stock	7500	$4.12	D
Stock Option (Right to Buy)	⁽⁸⁾	1/19/2028	Common Stock	12250	$4.65	D

Explanation of Responses:
(1)	Includes (a) 2,334 shares subject to a restricted stock unit award ("RSU") of common stock that was granted on January 19, 2018 under the Issuer's 2014 Equity Incentive Plan, of which one-third of the original 7,000 shares subject to the RSU vested or shall vest on each one year anniversary of the grant date of the award; and (b) 15,111 shares subject to an RSU of common stock that was granted on January 3, 2020 under the Issuer's 2014 Equity Incentive Plan, of which one-third of the original 22,666 shares subject to the RSU vested or shall vest on each one year anniversary of the grant date of the award.
(2)	25% of the shares subject to the option will vest on each one year anniversary of the grant date of March 31, 2020.
(3)	25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date of January 3, 2020.
(4)	One-third of the shares subject to the option vested or will vest on each one year anniversary of the grant date of July 31, 2019.
(5)	25% of the shares subject to the option vested or will vest on each one year anniversary of the grant date of January 15, 2019.
(6)	One-third of the shares subject to the option vested on the grant date and one-third of the shares subject to the option vested on each one year anniversary of the grant date of August 31, 2018.
(7)	25% of the original 30,000 shares subject to the option vested on the grant date and 25% of the original 30,000 shares subject to the option vested or will vest on each one year anniversary of the grant date of April 30, 2018.
(8)	25% of the original 24,500 shares subject to the option vested or will vest on each one year anniversary of the grant date of January 19, 2018.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
ZANTE GREG C/O VIKING THERAPEUTICS, INC. 12340 EL CAMINO REAL, SUITE 250 SAN DIEGO, CA 92130			Chief Financial Officer